Jeffrey A. Barnes

Hematology

55 Fruit St
Boston, MA 02114

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium.

Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium.

Journal: Leukemia & lymphoma

Published: March 14, 2026

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Journal: Blood advances

Published: February 24, 2026

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Journal: Blood

Published: January 13, 2026

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Journal: Blood

Published: January 13, 2026

Central nervous system involvement in chronic lymphocytic leukemia: a real-world analysis.

Central nervous system involvement in chronic lymphocytic leukemia: a real-world analysis.

Journal: Leukemia & lymphoma

Published: November 18, 2025

Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma.

Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma.

Journal: Journal of hematology & oncology

Published: August 27, 2025

Disparities in immunotherapy treatment for mycosis fungoides and Sézary syndrome in the National Cancer Database.

Disparities in immunotherapy treatment for mycosis fungoides and Sézary syndrome in the National Cancer Database.

Journal: Journal of the American Academy of Dermatology

Published: July 06, 2025

A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma.

A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma.

Journal: Blood advances

Published: May 13, 2025

A prospective study of prophylactic dexamethasone with glofitamab in relapsed/refractory large B-cell lymphoma.

A prospective study of prophylactic dexamethasone with glofitamab in relapsed/refractory large B-cell lymphoma.

Journal: Blood neoplasia

Published: May 05, 2025

Secondary Cancer Risk Among Patients With Primary Cutaneous B-cell Lymphoma.

Secondary Cancer Risk Among Patients With Primary Cutaneous B-cell Lymphoma.

Journal: JAMA dermatology

Published: April 30, 2025

A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomas.

A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomas.

Journal: Leukemia & lymphoma

Published: March 26, 2025

Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia/lymphoma.

Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia/lymphoma.

Journal: British journal of haematology

Published: March 21, 2025

Showing 1-12 of 59

Last Updated: 09/26/2026